Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective

Heinz, Katja C.; Willems, D.; Hiligsmann, Mickaël

doi:10.1080/13696998.2022.2059220

Cited by 12 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This information includes the annual treatment dropout rate, "remission" periods, subsequent treatment e cacy, costs and rates of adverse events, and hospitalization risk. [24] In recent years, BT has generally been considered the best intervention for treating moderate-to-severe AD, with high safety, reduced side effects, and improved patient quality of life. [25] Beck et al [26] reported the results of several randomized, double-blind, placebo-controlled trials involving adult patients with moderate to severe AD.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the economic burden associated with comparing biological therapy to traditional conventional therapies for the treatment of moderate-to-severe atopic dermatitis.

WANG,

LI,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Atopic dermatitis (AD) is a chronic, relapsing, and pruritic inflammatory skin disease with a high incidence rate, posing a considerable challenge for patients, society, and the healthcare system due to its chronic nature. In China, there is a scarcity of cost-effectiveness evidence concerning AD treatment. This study aimed to assess the cost-effectiveness of two prevalent treatments for moderate-to-severe AD—traditional conventional therapy (CT) and biological therapy (BT). Methods: A retrospective cohort study involving 97 patients with moderate-to-severe AD was conducted. Data were collected from a public tertiary dermatology hospital in Shandong Province, China. Primary outcome measures included total economic cost and treatment efficacy evaluated using the Severity Scoring of AD (SCORAD) index. The sustained treatment effect over six months was analyzed from a societal perspective. Results: This study included a total of 97 participants, with 47 receiving BT treatment and 50 receiving CT treatment. The entire treatment duration was 6 months, and the endpoint evaluation was the skin SCORAD score of the patients after 6 months of treatment. The average cost per person for BT was ¥28719.23, and for CT it was ¥8020.78. The cost-effectiveness ratio for BT was lower (¥34,609.82), signifying a lower cost per unit of effect gained. Patients utilizing CT incurred an additional expenditure of ¥31,853.56 for each additional unit of effectiveness compared to BT. Additionally, one-way sensitivity analysis underscored the cost of BT and its effectiveness as the most sensitive parameters in the model. Conclusion: BT emerged as the most cost-effective choice in the treatment of moderate-to-severe AD based on cost-effectiveness analysis. This research investment aids decision-makers in determining first-line treatment options for moderate-to-severe AD.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of the economic burden associated with comparing biological therapy to traditional conventional therapies for the treatment of moderate-to-severe atopic dermatitis.

WANG,

LI,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Currently, due to a lack of validated biomarkers, patients cannot be precisely assigned to subgroups determining that a certain agent would be the best therapeutic option. Another important aspect is financing novel treatments for patients, as the costs of such therapies are high [98]. However, despite the fact that these therapies are expensive, their efficacy can make them well worth the cost [99].…”

Section: Future Perspectives In the Personalized Treatment Of Admentioning

confidence: 99%

How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?

Mesjasz

Kołkowski

Wollenberg

et al. 2023

IJMS

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a heterogeneous disease in terms of its phenotypical, barrier, and immunological presentation. Emerging therapies are undoubtedly contributing to a new chapter in the treatment of AD, bringing an excellent possibility of individualization, and thereby creating a tailored approach. The two most promising substance groups are biological drugs (dupilumab, tralokinumab, lebrikizumab, nemolizumab) and Janus kinase inhibitors (JAKis) (baricitinib, upadacitinib, and abrocitinib). The vision that certain well-defined phenotypes and endotypes, as well as personal preferences, may guide the future treatment of AD is both tempting and appealing, but not yet reality. The accessibility of new drugs such as biologics and small molecules has opened up the discussion regarding personalized medicine, referring to the complex nature of AD as well as the experiences from clinical trials and real-world evidence. We have now reached the point of creating new strategies and AD treatment goals by increasing the amount of new information concerning the efficacy and safety of new drugs. This article has reviewed the novel treatment options for AD in the light of the heterogeneity of this disease and proposes a broader vision on the strategy of personalized treatment of AD.

show abstract

“…The U.S. Food and Drug Administration (FDA)‐approved drugs for moderate‐to‐severe (m‐s) AD are the biologics dupilumab (approved in 2017) and tralokinumab (approved in 2021), and the Janus kinase (JAK) inhibitors abrocitinib (approved in 2022) and upadacitinib (approved in 2022). Unfortunately, their use in daily practice faces limitations with respect to availability, costs 5 and concerns about possible (long‐term) side effects [e.g., the black box warning of the FDA on all JAK inhibitors for the treatment of m‐s AD 6,7 ]. Obstacles posed by such limitations become more apparent when one considers that 183 million (80%) of the 230 million people estimated to have eczema in 2010 lived in areas other than Europe or the high‐income regions of Asia and North America 8 …”

Section: Introductionmentioning

confidence: 99%

Methotrexate therapy for adult and paediatric moderate‐to‐severe atopic dermatitis: A PRISMA‐compliant meta‐analysis of data from daily practice

Wang,

Chen

2023

Aust J Dermatology

View full text Add to dashboard Cite

Of the 15 eligible studies identified via electronic searches in MEDLINE, EMBASE and CENTRAL in November 2022 for methotrexate therapy of moderate‐to‐severe atopic dermatitis, 12 were non‐randomized controlled trial (non‐RCT) studies with data from 437 patients (235 adults and 202 children). The response rates for short‐term therapy were 77% [95% CI 55‐99] (four studies; adults) – comparable to 81% [54‐100] of RCTs (two studies; adults) (p = 0.63) – and 61% [43‐79] (two studies; children), and for medium/long‐term therapy were 88.9% [74.3‐100.0] (four studies; adults) and 77.7% [61.5–94.0] (three studies; children). Children had a markedly lower rate of treatment discontinuation due to side effects [2.0% (five studies; children) vs. 14.9% (six studies; adults)], but were more likely to experience gastrointestinal disorders {relative risk (RR) 2.0 [1.44‐2.71]}, fatigue (RR 2.3 [1.35‐3.72]), headache (RR 2.8 [1.23‐5.61]), and infections (RR 2.9 [2.18‐3.58]). Other adverse events (children vs. adults) included hepatic disorders (32/176 vs. 35/305) and blood and lymphatic system/bone marrow disorders (25/148 vs. 19/184). Four serious adverse events were reported (children). Evidence from daily practice was limited by bias in the selection of participants in the study.

show abstract

Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective

Cited by 12 publications

References 21 publications

Analysis of the economic burden associated with comparing biological therapy to traditional conventional therapies for the treatment of moderate-to-severe atopic dermatitis.

Analysis of the economic burden associated with comparing biological therapy to traditional conventional therapies for the treatment of moderate-to-severe atopic dermatitis.

How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?

Methotrexate therapy for adult and paediatric moderate‐to‐severe atopic dermatitis: A PRISMA‐compliant meta‐analysis of data from daily practice

Contact Info

Product

Resources

About